There have been very few studies on the patterns of care and outcome of elderly (over 75 years) survivors with androgen independent prostate cancer (AIPC) who have been treated with docetaxel (Taxotere). The records of 175 French men with AIPC, over the age of 75 years, were retrospectively examined. All of the men were treated [...]
At the last ASCO Annual Meeting Saad et al. presented a report about a Phase II trial of custirsen (OGX-011) + docetaxel + prednisone vs. custirsen + mitoxantrone + prednisone in metastatic hormone-refractory prostate cancer. The subjects in the study had experienced relapses of cancer progression within 6 months of treatment with first-line docetaxel therapy. [...]
Today’s New York Times had an article written by Jane Brody that discusses the painful issues surrounding the decision to stop treatment, and its negative side effects, and let a cancer survivor live their last weeks in relative peace. This is always a difficult decision as many of us wish to hold on to life, [...]
Last April HealthDay News ran an article about chemotherapy and patients fear about starting it. Most cancer survivors involved in a recent survey reported that they had been fearful of undergoing chemotherapy. The good news is that most also said the treatments were much less difficult than they had expected. The truly startling fact is [...]
You are scheduled for chemotherapy (Taxotere if you are being treated for prostate cancer) in a few days, so you stop eating until you complete the therapy session! This scenario could become typical in future treatment protocols. Published last week in Proceedings of the National Academy of Sciences was a study that found that starving [...]
During radiation and chemotherapy, cancer patients including prostate cancer patients, should avoid the routine use of antioxidant supplements unless approved by their doctor. Supplements may reduce the anticancer benefits of therapy, researchers concluded in a commentary published online in the Journal of the National Cancer Institute. Radiation and Taxotere used for advanced prostate cancer therapy [...]
Taxotere (chemotherapy for prostate cancer) is administered intravenously usually in an cancer center or a hospital setting. Often the areas which are designated for chemo administration are referred to as infusion centers. Taxotere is administered with either on a higher dosage schedule of once every three weeks (q3wk) or a lower dosage schedule of once [...]
The current standard of care in the treatment of prostate cancer is to use chemotherapy (Taxotere) only in late stage hormone refractory prostate cancer. Most other cancers use chemotherapy agents at a much earlier stage then used for prostate cancer. Prostate cancer cells divide at a rate that is not much faster than normal cell [...]
Many of us think that chemotherapy for prostate cancer only involves the use of Taxotere. Just for the sake of accuracy, I want to clarify that almost every drug we take to treat prostate cancer is chemotherapy. Chemotherapy drugs are the drugs that are designed to kill cells. All of the drugs used as a [...]
